This matters for GLP-1 patients because the Paschou 2025 review identified reduced cellular ATP production as one of the proposed mechanisms by which GLP-1 medications may affect skin
This article follows our recent announcement that Vivani has entered into an agreement with Novo Nordisk to evaluate our semaglutide implant, NPM-139, for chronic weight management
There's a good reason why there's been some buzz around the ingredient recently
Harlow SD, Gass M, Hall JE, et al
Womens Wellness of Mississippi can help you create a safe, personalized postpartum plan, whether youre exploring semaglutide, looking for safe weight loss, or balancing lactation with your health goals
GLP-1 receptor activation contributes glucose-dependent insulin secretion and central appetite suppression